Welcome

The 2016 AACI/CCAF Annual Meeting convenes directors and executive-level administrators of cancer centers that are members of the Association of American Cancer Institutes (AACI) with leaders of national cancer research and advocacy groups, industry, and government health agencies to develop solutions to common challenges and to share best practices.

The cancer centers represented by AACI form North America’s cancer research infrastructure and are hubs of vital discoveries, treatment advances and improvements in patient care.

This year’s program, jointly formulated by AACI and the Cancer Center Administrators Forum (CCAF), includes an opening keynote presentation by Richard Pazdur, MD, acting director of the Food and Drug Administration’s Oncology Center of Excellence. It also features three panel discussions focused on precision medicine, along with an update about AACI’s Academic Difference Initiative, led by AACI President George J. Weiner, MD. The precision medicine presentations will highlight the creation and management of molecular tumor boards, efforts to facilitate precision medicine collaboration, and in-house versus outsourced molecular testing.

The program also includes a report from NCI Acting Director Douglas R. Lowy, MD, along with panel discussions about operational challenges in cell therapy trials, new and emerging genomic technologies for early detection and prevention of cancer, insights into successful submissions for cancer center support grants, and approaches to addressing administrative and regulatory burdens in cancer research trials.

No other event provides information on cancer research and patient care issues as they pertain to academic cancer center leaders, and provides them with a forum to discuss common issues. On behalf of the 2016 AACI/CCAF Annual Meeting Program Committee, welcome to Chicago!

Sincerely,
Barbara Duffy Stewart, MPH
AACI Executive Director
Program Committee

Chair: Scott M. Lippman, MD
UC San Diego Moores Cancer Center

Howard Bailey, MD
University of Wisconsin Carbone Cancer Center

Chad A. Ellis, PhD
UNC Lineberger Comprehensive Cancer Center
University of North Carolina at Chapel Hill

Stanton L. Gerson, MD
Case Comprehensive Cancer Center, Case Western Reserve University, Seidman Cancer Center at University Hospitals Case Medical Center

Kimberly F. Kerstann, PhD
Winship Cancer Institute of Emory University

Karen E. Knudsen, PhD
Sidney Kimmel Cancer Center at Thomas Jefferson University

Leonidas C. Platanias, MD, PhD
The Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Garth Powis, PhD
Sanford Burnham Prebys Medical Discovery Institute

Barbara Duffy Stewart, MPH
Association of American Cancer Institutes

Jeff A. Walker, MBA
The Ohio State University Comprehensive Cancer Center- James Cancer Hospital & Solove Research Institute

George J. Weiner, MD
Holden Comprehensive Cancer Center
University of Iowa

All 2016 AACI/CCAF Annual Meeting sessions will be held in the Grand Ballroom, River Level II, except where indicated.

Agenda

All sessions held in the Grand Ballroom, River Level II, except where indicated.

Sunday, October 23

11:00 am  Meeting Registration Begins
Grand Court, River Level II

11:00 am  Exhibits Open
Grand Court, River Level II

12:30 pm  Welcome and AACI Business Meeting

President’s Report
Dr. George J. Weiner
Holden Comprehensive Cancer Center
University of Iowa

Executive Director’s Report
Ms. Barbara Duffy Stewart
Association of American Cancer Institutes

Treasurer’s Report
Mr. Jeff Walker
The Ohio State University Comprehensive Cancer Center
James Cancer Hospital & Solove Research Institute

Program Chair’s Report
Dr. Scott M. Lippman
UC San Diego Moores Cancer Center

CCAF Report
Dr. Chad A. Ellis
UNC Lineberger Comprehensive Cancer Center
University of North Carolina at Chapel Hill

1:15 pm  Expediting Oncology Drug Approvals in an Era of Breakthrough Therapies

Dr. Pazdur will focus his talk on the current state of drug development in the era of precision medicine and immuno-oncology, as viewed from his unique perspective as both a regulator and an advocate.

Dr. Richard Pazdur
US Food and Drug Administration (FDA)

2:15 pm  Break

Program Subject to Change
## Agenda

### Sunday, October 23 continued

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:30 pm</td>
<td><strong>Academic Difference Initiative: Cancer Centers’ Impact on Patient Care, Research, Education, and the Local Economy</strong></td>
</tr>
<tr>
<td></td>
<td>To ensure that academic cancer centers are able to thrive well into the future, they must convey their unique role to a broad range of constituents—patients, payers, policy makers, university leadership, community oncology partners and the general public. As part of the first phase of its Academic Difference Initiative—headed by AACI President Dr. George Weiner—AACI has gathered evidence showing the value of academic cancer centers. The second phase will involve disseminating the gathered information. The panel will discuss the initiative’s progress and how cancer centers can use the information.</td>
</tr>
<tr>
<td></td>
<td><strong>Moderator: Dr. George J. Weiner</strong>  <strong>Holden Comprehensive Cancer Center</strong>  <strong>University of Iowa</strong>  <strong>Ms. Judy Fortin</strong>  <strong>Winship Cancer Institute of Emory University</strong>  <strong>Ms. Anne L. Levine</strong>  <strong>Dana-Farber Cancer Institute</strong>  <strong>Dr. Julie Wolfson</strong>  <strong>University of Alabama Birmingham</strong></td>
</tr>
</tbody>
</table>
| 3:30 pm   | **Advancing National Cancer Care Through Cancer Center-Based Networks—a Moonshot Summit Response**  
AACI views as a priority the advancement of integrated patient care, expansion of individual cancer center networks to improve clinical trials access, and working across centers to share best practices. Dr. Gerson will provide an overview of his proposed Presidential Initiative focused on AACI centers’ role in integrating advances in cancer treatment into the community.  
**Dr. Stanton L. Gerson**  **Case Comprehensive Cancer Center, Case Western Reserve University Seidman Cancer Center at University Hospitals Case Medical Center**  
| 4:00 pm   | **General Sessions End**  

### Monday, October 24

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 4:00 pm   | **CCAF Business Meeting**  *(closed session)*  
| 4:00 pm   | **4th Annual AACI Physician Clinical Leadership Initiative Meeting**  *(previous RSVP required)*  **Promenade Ballroom BC, River Level II**  
| 6:00–7:30 pm | **Welcome Reception**  **Grand Court, River Level II**  
| 7:00 am   | **General Breakfast**  **Promenade Ballroom AB, River Level II**  
| 7:00 am   | **Exhibits Open**  **Grand Court, River Level II**  
| 7:15 am   | **Election Preview: Presidential and Congressional Races and the Impact on Cancer Centers**  *(session not CME accredited)*  **Promenade Ballroom C, River Level II**  
|           | With the 2016 General Election just weeks away, Mr. Frommer will discuss the Presidential contest as well as key House and Senate races, highlighting retirements and toss-ups and the impact the outcome might have on cancer centers. He will also discuss prospects for NIH funding in this and the next Congress.  
**Mr. Ross A. Frommer**  **Columbia University Medical Center**  
| 8:00 am   | **Setting the Bar for Creating and Managing Molecular Tumor Boards**  
The rise of molecular testing has transformed the role of the traditional tumor board at a growing number of cancer centers, leading to creation, or at least contemplation, of a new entity focused on evolving technologies and genomics. Panelists will discuss the structure of molecular tumor boards at various institutions, including management issues such as meeting frequency and agendas, operations, and board composition.  
**Continued on page 6**
8:00 am  Setting the Bar for Creating and Managing Molecular Tumor Boards

Moderator: Dr. Stanton L. Gerson
Case Comprehensive Cancer Center, Case Western Reserve University
Seidman Cancer Center at University Hospitals Case Medical Center

Dr. Aaron Bossler
Holden Comprehensive Cancer Center
University of Iowa

Dr. Christopher Holmes
Case Comprehensive Cancer Center, Case Western Reserve University
Seidman Cancer Center at University Hospitals Case Medical Center

Dr. Barbara Parker
UC San Diego Moores Cancer Center

9:00 am  Facilitating Precision Medicine Collaboration

A national spotlight is shining on precision medicine collaboration, thanks to President Obama’s launch of a Precision Medicine Initiative in 2015, followed by Vice President Biden’s emphasis on cancer research collaboration as part of the administration’s Cancer Moonshot. Panelists will explore their potential roles in the government’s drive to eradicate cancer, along with obstacles, including the proprietary nature of data and other outcomes resulting from their work.

Moderator: Dr. Karen E. Knudsen
Sidney Kimmel Cancer Center at Thomas Jefferson University

Dr. Philippe Bedard
Princess Margaret Cancer Centre

Dr. Michael A. Caligiuri
The Ohio State University Comprehensive Cancer Center
James Cancer Hospital & Solove Research Institute

Dr. Michael Pellini
Foundation Medicine Inc.

Dr. Joe V. Selby
Patient-Centered Outcomes Research Institute (PCORI)

Dr. Ellen V. Sigal
Friends of Cancer Research

10:00 am  Pros and Cons: In-House Versus Outsourced Molecular Testing

With molecular testing now a well-established component of cancer care, cancer centers are searching for optimal, cost-effective means of delivering these services to patients. A prime consideration is whether to conduct the testing in-house or send it out to commercial enterprises specializing in such analysis. Variables such as insurance reimbursement, sample and sequencing costs, and quality control standards figure into the decision. Panelists will discuss approaches to molecular testing, including the pros and cons of outsourced versus in-house testing, as well as the role of molecular tumor boards.

Moderator: Dr. Norman Sharpless
UNC Lineberger Comprehensive Cancer Center
University of North Carolina at Chapel Hill

Dr. John Iafrate
Massachusetts General Hospital

Dr. Mark A. Rubin
Weill Cornell Medical College

Dr. Vivek Subbiah
Division of Cancer Medicine and Division of Pediatrics
University of Texas MD Anderson Cancer Center

11:00 am  AACI Distinguished Scientist Award

Immune Checkpoint Blockade in Cancer Therapy: New Insights, Opportunities and Prospects for a Cure

Dr. Allison will discuss the origins, current status, and future directions of checkpoint blockade in immunological approaches to cancer therapy. This new approach to therapy is potentially curative in subpopulation of patients with several types of cancer, and efforts are underway to unravel the cellular and molecular involved in order identify predictive biomarkers, and bring its benefits with more patients with more types of cancer.

Dr. James P. Allison
University of Texas MD Anderson Cancer Center

12:00 pm  AACI Public Service Awards

2016 AACI Distinguished Public Service Award
The Honorable Tom Cole (R-OK)

2016 AACI Distinguished Public Service Award
The Honorable Marcia L. Fudge (D-OH)

12:15 pm  Luncheon  Promenade Ballroom, River Level II
2:15 pm  Operational Challenges in Cell Therapy Trials
Improving cancer patient outcomes is an ongoing struggle for cancer centers. Cell therapy trials offer one way to tackle the problem. Operationalizing such trials entails difficult challenges including scientific merit determinations, quality oversight, monitoring, correcting protocol deviations and reviewing adverse events. Panelists will probe cell therapy operational issues as they affect, and are influenced by, treatment of both adult and pediatric cancers and hematological and solid tumors.

Moderator: Dr. Steve A. Grupp
Children’s Hospital of Pennsylvania

Dr. Terry J. Fry
National Cancer Institute

Dr. Helen Heslop
The Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine

Dr. Dean Anthony Lee
Nationwide Children’s Hospital
The Ohio State University Comprehensive Cancer Center

3:30 am  Break

3:45 am  Concurrent Sessions
Genomic Markers for Cancer Prevention and Early Detection
Astor Ballroom, River Level I

The advent of new genomic technologies has expanded the range of strategies for early cancer detection and prevention, with researchers identifying a genomic marker found in five different cancers that could lead to a simple early detection blood test. Topics covered will include the first genomic markers validated for early detection, new liquid-biopsy technology, and the proposed Precancer Genome Atlas as a precancer “moonshot” aligned with the Obama/Biden cancer initiative.

Moderator: Dr. Avrum Spira
Boston University Cancer Center

Dr. Sanford Markowitz
Case Comprehensive Cancer Center, Case Western Reserve University
Seidman Cancer Center at University Hospitals Case Medical Center

Dr. Nitzan Rosenfeld
Cancer Research UK Cambridge Institute

5:00 pm  Sessions End

8:30–11:00 pm  Hospitality Suite  Riverfront Room, Lobby Level

Tuesday, October 25

7:00 am  General Breakfast  Promenade Ballroom, River Level II

7:00 am  CCSG Roundtable Discussions  Riverfront Room, Lobby Level

7:00 am  Exhibits Open  Grand Court, River Level II

Program Subject to Change
8:00 am  Promoting High-Level, System-Wide Changes to Address Administrative and Regulatory Burdens in Cancer Research Trials

The moderator, Dr. Paul Martin, will lead a discussion about preferred high level system-wide changes and panelists will: Rank order the solutions discussed in the report according to importance and feasibility; determine obstacles to implementing the solutions; and, discuss which solutions should be tackled first to make the biggest impact, which should be deferred, and who should take the lead in implementing solutions.

Moderator: Dr. Paul J. Martin
Fred Hutchinson Cancer Research Center

Dr. Randall F. Holcombe
University of Hawaii Cancer Center
University of Hawaii at Manoa

Dr. Carrie Lee
UNC Lineberger Comprehensive Cancer Center
University of North Carolina at Chapel Hill

Dr. George J. Weiner
Holden Comprehensive Cancer Center
University of Iowa

9:15 am  NCI Director’s Report

The federal Precision Medicine Initiative and the National Cancer Moonshot show that there has never been a more exciting era in cancer research. Though U.S. cancer mortality rates have declined and survival rates have increased since the mid-1990s, we still have a long way to go. Three-quarters of NCI investigator-initiated awards go to NCI-designated cancer center researchers who are rapidly working to develop new technologies and speed progress. NCI Acting Director Douglas R. Lowy, MD, will address NCI budgeting challenges and identify opportunities for collaboration among academia, government, and the private sector.

Dr. Douglas R. Lowy
National Cancer Institute

10:30 am  New Molecular Tools and Technologies

Forward-thinking technologies are transforming our understanding of cancer and how those affected by the disease receive care and treatment. This session will focus on breakthrough areas of research including nanotechnology, liquid biopsy, DNA studies involving clustered regularly-interspaced short palindromic repeats (CRISPR) and the alteration of activity in specific genes through the application of small interfering RNA (siRNA).

Moderator: Dr. Garth Powis
Sanford Burnham Prebys Medical Discovery Institute

Dr. David A. Giljohann
Exicure, Inc.

Dr. Itay Tirosh
Broad Institute of MIT and Harvard

11:30 am  Update on the NCI Cancer Centers Program

This session provides an opportunity for an open dialogue about the NCI’s programmatic priorities, policies, strategies and goals for the national cancer research enterprise. A discussion about the merits and challenges of these new priorities will contribute to the optimal use of limited federal cancer research funds at AACI cancer centers.

Dr. Henry P. Ciolino
National Cancer Institute

12:15 pm  Adjourn
Continuing Medical Education

Joint Providership Statement
Jointly provided by the American Association for Cancer Research and the Association of American Cancer Institutes.

Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American Association for Cancer Research and the Association of American Cancer Institutes. The American Association for Cancer Research is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
The American Association for Cancer Research designates this live activity for a maximum of 15.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit certification for individual sessions may vary, dependent upon compliance with the ACCME Accreditation Criteria. The final number of credits may vary from the maximum number indicated above.

Learning Objectives
Physicians and other health care professionals who attend the meeting should be able to summarize the program content, discuss its application in clinical practice, and convey the information to administrators at their centers. As part of the program’s learning objectives, all attendees should be able to describe and discuss:

- Expediting oncology drug approvals.
- The value of the academic cancer center.
- The progress of the National Cancer Moonshot.
- Creating and managing molecular tumor boards.
- The complexities of implementing precision medicine at cancer centers.
- Approaches to providing genetic testing to patients.
- The challenges associated with operationalizing cell therapy trials.
- New and emerging genomic technologies used for early detection and prevention of cancer.
- NCI’s priorities, policies, strategies and goals for the national cancer research enterprise, and their relationship to academic cancer centers.
- Forward-thinking technologies which are changing cancer care delivery.

Continuing Medical Education

Americans with Disabilities Act
It is the policy of the American Association for Cancer Research and the Association of American Cancer Institutes not to discriminate against any person on the basis of disabilities. If you feel you need services or auxiliary aids mentioned in this act in order to fully participate in this continuing education activity, please contact Jaime Anderson at 412-647-3845 or attach a note to your registration form.

Faculty Disclosure
It is the policy of the American Association for Cancer Research and the Association of American Cancer Institutes to require disclosure of financial relationships from individuals in a position to control the content of a CME activity; to identify and resolve conflicts of interest related to those relationships; and to make disclosure information available to the audience prior to the CME activity. Presenters are required to disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentations.

Target Audience
This trans-disciplinary conference is designed for basic and clinical scientists, as well as for physician-scientists from academia, industry, government, and other institutions with interest in innovative systems and technologies for diagnosing, preventing, and treating cancer and its long-term effects.

Leaders of AACI’s 95 academic and freestanding cancer research centers, including cancer center directors, executive administrators, and other top scientific and clinical leaders—leaders from industry and government agencies as well as those of cancer research and advocacy organizations attend the meeting. All attendees have a significant impact on cancer research and patient care. The attendees are medical professionals, including oncologists, pharmacists, radiologists, nuclear medicine physicians, nurses, social workers, psychologists, cancer communication specialists, public health leaders, and other faculty members who focus on cancer.
Awardee Profiles

2016 AACI Distinguished Scientist Award

Dr. James P. Allison  
University of Texas MD Anderson Cancer Center

Dr. James P. Allison joined the University of Texas MD Anderson Cancer Center in 2012, where he is Professor of Immunology, Chair of the Department of Immunology, and Executive Director of the Immunotherapy Platform.

His fundamental discoveries include the definition of the structure of the T cell antigen receptor, demonstration that the T cell molecule CD28 provides costimulatory signals necessary for full T cell activation, and identification of the inhibitory checkpoint molecule CTLA-4, which inhibits activated T cells. He proposed that immune checkpoint blockade might be a powerful strategy for therapy of many cancer types, and conducted preclinical experiments showing its potential. The development of immune checkpoint blockade transformed cancer therapy and has been responsible for saving the lives of thousands of cancer patients.

Dr. Allison was involved in the development of Ipilimumab, which was approved by the FDA for treatment of metastatic melanoma in 2011. In 2014, the FDA approved two antibodies to PD-1, a related immune checkpoint, for the treatment of melanoma. In 2015 the FDA approved five additional CTLA-4 and PD-1 antibodies and combinations of both for the treatment of a variety of additional indications, including melanoma, lung, and kidney cancer.

Dr. Allison obtained his BS and PhD from The University of Texas at Austin. After a postdoctoral fellowship at Scripps Clinic and Research Foundation he joined the faculty of the University of Texas MD Anderson Cancer Center Science Park in Smithville, Texas, in 1974 as Asistant Biochemist. He moved to the University of California, Berkeley in 1984 as Professor of Immunology. At Berkeley he served as Director of the Cancer Research Laboratory, Head of the Division of Immunology in the Department of Molecular and Cell Biology, and Co-chair of the Department of Molecular and Cell Biology. In 2004 he moved to the Memorial Sloan Kettering Cancer Center in New York City, where he was Professor of Immunology, Chair of Immunology and Director of the Ludwig Center for Cancer Immunotherapy.

The AACI Distinguished Scientist Award acknowledges extraordinary scientific accomplishments and contributions to cancer research. Previous honorees are Lewis Cantley, Brian Druker, Lee Hartwell, Mary-Claire King, Timothy Ley, Janet Rowley, Stuart Schreiber, Margaret R. Spitz, Bert Vogelstein, Robert Weinberg and Irving Weissman.

Awardee Profiles

2016 AACI Distinguished Public Service Award

The Honorable Tom Cole  
United States House of Representatives

AACI recognizes U.S. Representative Tom Cole (R-OK) with its 2016 Distinguished Public Service Award for his dedicated efforts on behalf of cancer patients and medical research. Rep. Cole is chairman of the House Appropriations Subcommittee on Labor, Health and Human Services, Education and Related Agencies, the subcommittee that funds medical research. He is working with Ranking Member Rosa DeLauro (D-NY) to fund the National Cancer Moonshot Initiative. Chairman Cole is a member of the Congressional Childhood Cancer Caucus.

Chairman Cole was elected to Congress in 2002 and is currently serving in his seventh term in the House. He co-sponsored the Conquer Childhood Cancer Act of 2007, a bill to advance medical research and treatments into pediatric cancers, ensure patients and families have access to the current treatments and information regarding pediatric cancers, establish a population-based national childhood cancer database, and promote public awareness of pediatric cancers. Chairman Cole holds a B.A. from Grinnell College, an M.A. from Yale University and a Ph.D. from the University of Oklahoma.

The Honorable Marcia L. Fudge  
United States House of Representatives

AACI recognizes U.S. Representative Marcia L. Fudge (D-OH) with its 2016 Distinguished Public Service Award for her dedicated efforts on behalf of cancer patients and medical research. Rep. Fudge is a co-sponsor of the Breast Cancer Patient Protection Act which seeks to require that health plans provide coverage for a minimum hospital stay for mastectomies, lumpectomies, and lymph node dissection for the treatment of breast cancer and coverage for secondary consultations.

First elected in 2008, Rep. Fudge serves on the House Committee on Agriculture and the House Committee on Education and the Workforce. She is the Ranking Member on the Subcommittee on Early Childhood, Elementary and Secondary Education and immediate past Chair of the Congressional Black Caucus.

Last year, Rep. Fudge participated in a news conference with Case Western Reserve University School of Medicine to present original, groundbreaking colon cancer research. The research was made possible with a National Cancer Institute grant to establish a Specialized Program of Research Excellence in Gastrointestinal Cancers at Case Comprehensive Cancer Center.
Keynote Speaker

Dr. Richard Pazdur
U.S. Food and Drug Administration

Richard Pazdur, MD, is Acting Director, Oncology Center of Excellence, United States Food and Drug Administration (FDA). His opening keynote talk for the 2016 AACI/CCAF Annual Meeting focuses on the current state of drug development in the era of precision medicine and immuno-oncology as viewed from his unique perspective as both a regulator and an advocate.

The FDA’s Oncology Center of Excellence (OCE) leverages the combined skills of the FDA’s regulatory scientists and reviewers with expertise in drugs, biologics and devices to expedite the development of novel cancer products as part of the Vice President’s National Cancer Moonshot Initiative. In his role as OCE acting director, Dr. Pazdur is responsible for leading the effort to develop and execute an integrated regulatory approach to enhance the cross-center coordination of oncology product clinical review.

Dr. Pazdur previously served as the director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research. That office was formed in 2005 to consolidate the review of drugs and therapeutic biologics for the diagnosis, treatment, and prevention of cancer as well as the review of drugs and therapeutic biologics for hematologic diseases and for medical imaging. Dr. Pazdur’s position facilitated coordination of oncology activities across all FDA centers and ensured an ongoing outreach and collaboration between FDA, the National Cancer Institute, and other cancer-related organizations within and outside of the government.

Dr. Pazdur was the Director of the Division of Oncology Drug Products from September 1999 to May 2005. Prior to joining the FDA, Dr. Pazdur was Professor of Medicine at The University of Texas MD Anderson Cancer Center in Houston, Texas. Dr. Pazdur was on the faculty of the MD Anderson Cancer Center from 1988 to 1999.

Support

Acknowledgment of Commercial Support

The American Association for Cancer Research and the Association of American Cancer Institutes express appreciation to the following companies for their support of this educational activity by providing an unrestricted educational grant:

- Amgen
- Astellas
- AstraZeneca
- Genomic Health, Inc.
- Gilead
- Huron Consulting Group
- Lilly
- Merck
- Novartis
- Pfizer
- Tyler & Company

Acknowledgment of Programmatic Support

The Association of American Cancer Institutes gratefully acknowledges the following organizations for providing program and activity support:

- Amgen
- Astellas
- Bristol-Myers Squibb
- Complion
- Forte Research Systems
- Genentech
- Gilead
- Janssen Research & Development
- Lilly
- Merck
- Nimblify, a Forte Company
- Pfizer
- Takeda Oncology
- Velos

Support as of October 6, 2016
The American Association for Cancer Research and the Association of American Cancer Institutes express appreciation to the following companies for their support of this educational activity by providing exhibit fees:

**Exhibitors**

The American Association for Cancer Research and the Association of American Cancer Institutes express appreciation to the following companies for their support of this educational activity by providing exhibit fees:

**Complion**
Complion is a document management and workflow platform for clinical research sites. Built by clinical researchers for clinical researchers, it transforms the way clinical trial documentation is maintained. Leading physicians, hospitals, academic medical centers, health systems and cancer centers around the country leverage Complion to reduce regulatory burden, improve compliance and streamline operations. See what Complion can do for you by visiting www.complion.com.

**ECG Management Consultants**
ECG is a national consulting firm that is leading healthcare forward, using the knowledge and expertise built over the course of four decades to help clients see clearly where healthcare is going and to navigate toward success. With particular expertise in cancer services strategy and planning, ECG consultants work as trusted, professional partners with academic medical centers, hospitals, health systems, and medical groups across the country. We thrive on developing smart strategies and pragmatic solutions to the critical challenges that will revolutionize the healthcare system. To learn more about our strategy, finance, operations, and technology services, visit us at www.ECGMC.com.

**Forte Research Systems®**
Forte Research Systems® is a technology partner for all research needs. Forte’s OnCore Enterprise Research® system supports efficient research, compliance, data management and budgetary processes at academic medical centers, cancer centers, and healthcare systems across the U.S. Its OnCore user community, Onsemble, facilitates standardization and collaboration with thousands of researchers across the industry. Forte Research recently added two new solutions to its ecosystem to support research professionals.

Opus™ streamlines the process of preparing grant applications, renewals, and progress reports by serving as a repository of all research activities and accomplishments. Opus helps research organizations complete grant submission prep work in a fraction of the time.

Research Insights™ is a data platform that informs strategic decision-making and increases operational efficiencies with its flexible and interactive dashboards that cover multiple aspects of clinical research operations. Organizations use the visualized data to assess their portfolio and resources, determine needs and strategically plan next steps.

**Foundation Medicine**
Foundation Medicine (NASDAQ:FMI) is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient’s unique cancer. The company offers a full suite of comprehensive genomic profiling assays, FoundationOne®, FoundationOne Heme® and FoundationACT™, to identify the molecular alterations in a patient’s cancer and match them with relevant targeted therapies, immunotherapies and clinical trials. Foundation Medicine’s molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. For more information, please visit http://www.FoundationMedicine.com or follow Foundation Medicine on Twitter (@FoundationATCG).

**iLab Solutions, part of Agilent Technologies**
iLab Solutions, now part of Agilent Technologies, is the leader in providing web-based core management services to research institutions. Its functionality includes request management, storeroom management, sample processing, equipment reservation management, usage tracking, billing and invoicing, reporting, and lab requisitioning and spend tracking tools.

**Intellisphere/OncLive**
The OncLive Strategic Alliance Partnership program is a mutually beneficial program designed to help promote research, faculty and outreach programs from leading cancer centers across the nation through the use of our numerous oncology print publications and digital assets, including OncLive.com. It truly is a content relationship with no monetary exchange. This is an excellent opportunity to gain additional exposure and extend your reach to a national audience of oncology professionals.

Through the partnership, faculty members would be able to submit content for a plethora of oncology publications including OncologyLive & Oncology Nursing News. Not only would faculty be published in our print materials but on our website as well. Through video interviews and web–based features, Strategic Alliance Partners receive a dedicated landing page on OncLive.com to showcase and highlight their research and initiatives.

**Precision Imaging Metrics**
Precision Imaging Metrics helps cancer centers across the country produce higher-quality and timelier imaging data, enhancing clinical trials and patient care. In 2004, Drs. Gordon Harris and Annick Van den Abbeele founded the Tumor Imaging Metrics Core (TIMC) at the Dana Farber/Harvard Cancer Center (DF/HCC). Since its inception, TIMC has analyzed over 70,000 scans for over 1500 clinical trials. This vast experience is the foundation on which Precision Imaging Metrics — and its flagship Metrics Manager application — has been built. The Metrics Manager application is currently in use by DF/HCC, Yale Cancer Center, Fred Hutchinson Cancer Research Center, Huntsman Cancer Institute, Massey Cancer Center, and will be implemented at Winship Cancer Center this fall. Please visit www.precisionmetrics.org for more information or email support@precisionmetrics.org to schedule a demo.
In compliance with the standards set by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of the American Association for Cancer Research (AACR) that the information presented at CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, the AACR has provided information that planning committee members, speakers, and abstract presenters have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this CME activity. Relationships are abbreviated as follows: E, Employee of listed company; G, Grant/research support recipient; A, Advisor or review panel member; C, Consultant; S, Stock Shareholder; SB, Speakers’ Bureau; H, Honoraria; O, Other.

<table>
<thead>
<tr>
<th>Last Name</th>
<th>First Name</th>
<th>Member Name</th>
<th>Relationships</th>
<th>Type</th>
<th>Role</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allison</td>
<td>James</td>
<td>University of Texas MD Anderson Cancer Center</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Bailey</td>
<td>Howard</td>
<td>University of Wisconsin Carbone Cancer Center</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Bedard</td>
<td>Philippe</td>
<td>Princess Margaret Cancer Centre, University Health Network</td>
<td>No Relationships</td>
<td>Program Committee</td>
<td></td>
</tr>
<tr>
<td>Bossler</td>
<td>Aaron</td>
<td>Holden Comprehensive Cancer Center, University of Iowa</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Caliguiri</td>
<td>Michael</td>
<td>The Ohio State University Comprehensive Cancer Center</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Cicalino</td>
<td>Henry</td>
<td>National Cancer Institute</td>
<td>No Relationships</td>
<td>Program Committee, Speaker</td>
<td></td>
</tr>
<tr>
<td>Ellis</td>
<td>Chad</td>
<td>UNC Lineberger Comprehensive Cancer Center</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Fortin</td>
<td>Judy</td>
<td>Winship Cancer Institute, of Emory University</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Frohmer</td>
<td>Ross</td>
<td>Herbert Irving Comprehensive Cancer Center, Columbia University</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Fry</td>
<td>Jerry</td>
<td>National Cancer Institute</td>
<td>No Relationships</td>
<td>Program Committee, Speaker</td>
<td></td>
</tr>
<tr>
<td>Gerson</td>
<td>Stanton</td>
<td>Case Comprehensive Cancer Center</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Gjofarrii</td>
<td>David</td>
<td>Exquare, Inc.</td>
<td>No Relationships</td>
<td>E, S</td>
<td>Speaker</td>
</tr>
<tr>
<td>Grupp</td>
<td>Steve</td>
<td>Children’s Hospital of Pennsylvania</td>
<td>No Relationships</td>
<td>C, G, A</td>
<td>Speaker</td>
</tr>
<tr>
<td>Halme</td>
<td>Dina</td>
<td>University of Virginia Cancer Center</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Heslop</td>
<td>Helen</td>
<td>The Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine</td>
<td>No Relationships</td>
<td>O</td>
<td>Speaker</td>
</tr>
<tr>
<td>Hofacker</td>
<td>Janie</td>
<td>Association of American Cancer Institutes</td>
<td>No Relationships</td>
<td>Program Committee, Speaker</td>
<td></td>
</tr>
<tr>
<td>Holmes</td>
<td>Christopher</td>
<td>Case Comprehensive Cancer Center</td>
<td>Merck, Bristol Myers Squibb, Roche/Genentech, Foundation Medicine, Inc.</td>
<td>G, S, A</td>
<td>Speaker</td>
</tr>
<tr>
<td>Holcombe</td>
<td>Randall</td>
<td>University of Hawaii Cancer Center</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Iaffaitte</td>
<td>John</td>
<td>Massachusetts General Hospital, Harvard Medical School</td>
<td>ArcherDx, Roche, Chugai</td>
<td>A, S</td>
<td>Speaker</td>
</tr>
<tr>
<td>Kentzian</td>
<td>Kimberly</td>
<td>Winship Cancer Institute of Emory University</td>
<td>No Relationships</td>
<td>Program Committee, Speaker</td>
<td></td>
</tr>
<tr>
<td>Knudsen</td>
<td>Karen</td>
<td>Sidney Kimmel Cancer Center at Thomas Jefferson University</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Lee</td>
<td>Dean</td>
<td>The Ohio State University Comprehensive Cancer Center</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Lee</td>
<td>Carrie</td>
<td>UNC Lineberger Comprehensive Cancer Center</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Levine</td>
<td>Anne</td>
<td>Dana-Farber Cancer Institute, Harvard Medical School</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Lippman</td>
<td>Scott</td>
<td>UC San Diego Moores Cancer Center</td>
<td>No Relationships</td>
<td>Program Committee, Speaker</td>
<td></td>
</tr>
<tr>
<td>Lowy</td>
<td>Douglas</td>
<td>National Cancer Institute</td>
<td>Merck, GlaxoSmithKline, Indian Immunologicals Ltd, Shantha Biotech, PpxVax, Acambis Inc.</td>
<td>O</td>
<td>Speaker</td>
</tr>
<tr>
<td>Markowitz</td>
<td>Sanford</td>
<td>Case Comprehensive Cancer Center</td>
<td>Exact Sciences, Janssen Pharmaceuticals, GlaxoSmithKline</td>
<td>O, C</td>
<td>Speaker</td>
</tr>
<tr>
<td>Martin</td>
<td>Paul</td>
<td>Fred Hutchinson Cancer Research Center</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Meminotit</td>
<td>Drew</td>
<td>Dana-Farber Cancer Institute, Harvard Cancer Center</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Mitchell</td>
<td>Robert</td>
<td>University of Maryland, Greenebaum Comprehensive Cancer Center</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Neuss</td>
<td>Michael</td>
<td>Vanderbilt-Ingram Cancer Center</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Parker</td>
<td>Barbara</td>
<td>UC San Diego Moores Cancer Center</td>
<td>GlaxoSmithKline, Genentech, Merck</td>
<td>G, S</td>
<td>Speaker</td>
</tr>
<tr>
<td>Pazdur</td>
<td>Richard</td>
<td>Food and Drug Administration</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Pellini</td>
<td>Michael</td>
<td>Foundation Medicine, Inc.</td>
<td>Foundation Medicine, Inc.</td>
<td>E</td>
<td>Speaker</td>
</tr>
<tr>
<td>Plattanias</td>
<td>Leonidas</td>
<td>The Robert H. Lurie Comprehensive Cancer Center of Northwestern University</td>
<td>No Relationships</td>
<td>Program Committee</td>
<td></td>
</tr>
<tr>
<td>Ploos</td>
<td>Garth</td>
<td>Sanford Burnham Prebys Medical Discovery Institute</td>
<td>Cascadia, Phus, Ensicyce</td>
<td>A, S</td>
<td>Program Committee, Speaker</td>
</tr>
<tr>
<td>Rosenfeld</td>
<td>Nitzan</td>
<td>Cancer Research UK Cambridge Institute</td>
<td>Invista, AstaZeneca</td>
<td>O, G</td>
<td>Speaker</td>
</tr>
<tr>
<td>Rubin</td>
<td>Mark</td>
<td>Weil Cornell Medical College</td>
<td>Eli Lilly &amp; Company, Janssen Pharmaceuticals</td>
<td>G</td>
<td>Speaker</td>
</tr>
<tr>
<td>Selby</td>
<td>Joe</td>
<td>Patient-Centered Outcomes Research Institute (PCOR)</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Sharpless</td>
<td>Norman</td>
<td>UNC Lineberger Comprehensive Cancer Center</td>
<td>G1 Therapeutics, Healthspan DX, Pfizer, GlaxoSmithKline, Merck</td>
<td>K, S, A, H, G</td>
<td>Speaker</td>
</tr>
<tr>
<td>Sigal</td>
<td>Ellen</td>
<td>Friends of Cancer Research</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Spira</td>
<td>Avrum</td>
<td>Boston University Cancer Center</td>
<td>Veracyte Inc., Janssen Pharmaceuticals</td>
<td>C, G</td>
<td>Speaker</td>
</tr>
<tr>
<td>Springer</td>
<td>Brian</td>
<td>Moffitt Cancer Center</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Stewart</td>
<td>Barbara</td>
<td>Association of American Cancer Institutes</td>
<td>No Relationships</td>
<td>Program Committee, Speaker</td>
<td></td>
</tr>
<tr>
<td>Subbiah</td>
<td>Vivek</td>
<td>University of Texas MD Anderson Cancer Center</td>
<td>Novartis, Bayer, Fujifilm</td>
<td>G</td>
<td>Speaker</td>
</tr>
<tr>
<td>Tirosh</td>
<td>Itay</td>
<td>Broad Institute of MIT and Harvard</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Von Roenn</td>
<td>James</td>
<td>American Society of Clinical Oncology</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Walker</td>
<td>Jeff</td>
<td>The Ohio State University Comprehensive Cancer Center</td>
<td>No Relationships</td>
<td>Program Committee, Speaker</td>
<td></td>
</tr>
<tr>
<td>Weiner</td>
<td>George</td>
<td>Holden Comprehensive Cancer Center, University of Iowa</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>Wolfsen</td>
<td>Julie</td>
<td>University of Alabama at Birmingham</td>
<td>No Relationships</td>
<td>Speaker</td>
<td></td>
</tr>
</tbody>
</table>